Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa + BCG vs BCG in High Risk Superficial Bladder Cancer
NCT00352079Phase 3Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in bladder cancer, sponsored by Canadian Cancer Trials Group. Started Jan 2007; status: terminated.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00352079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352079.